SIGHT SCIENCES INC. - COMMON STOCK

3,3200

08-января-25 16:45:00

15 мин. задержка

Акции

+0,0100

+0,30%

Сегодняшний диапазон

3,2000 - 3,3900

ISIN

N/A

Источник

NASDAQ

Sight Sciences Announces Real-World 36-Month Study Confirming Long-Term Effectiveness of Standalone OMNI Surgical System in Managing Primary Open-Angle Glaucoma

07 янв 2025 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Announces the Results of a Budget Impact Analysis for its TearCare® System for the Treatment of Meibomian Gland Disease (“MGD”) Showing Cost Savings Over Existing Reimbursed Treatment Options

19 дек 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences to Present at the Piper Sandler 36th Annual Healthcare Conference

19 ноя 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Reports Third Quarter 2024 Financial Results and Updates its Full Year 2024 Adjusted Operating Expense Guidance

07 ноя 2024 16:05:01 Источник Nasdaq GlobeNewswire
Sight Sciences Appoints MK Raheja as Executive Vice President, Research and Development and Brenton Taylor as Executive Vice President, Operations

07 ноя 2024 16:04:00 Источник Nasdaq GlobeNewswire
Sight Sciences to Report Third Quarter Financial Results on November 7, 2024

17 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire
Single TearCare® Treatment Improved Functional Visual Outcomes as well as Signs and Symptoms of Patients with Dry Eye Disease in Investigator-Initiated Trial

14 окт 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

20 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Reports Second Quarter 2024 Financial Results and Narrows Full Year 2024 Financial Guidance

01 авг 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

18 июл 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Announces the Release of its First Sustainability Report

10 июн 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

28 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

28 май 2024 08:30:01 Источник Nasdaq GlobeNewswire
Sight Sciences to Present at the Upcoming Bank of America Healthcare Conference

07 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Reports First Quarter 2024 Financial Results and Reaffirms Full Year 2024 Financial Guidance

02 май 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Announces Successful $34 Million Patent Infringement Verdict Against Alcon and its Hydrus Microstent for Microinvasive Glaucoma Surgery

29 апр 2024 08:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences to Report First Quarter Financial Results on May 2, 2024

18 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma

10 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting

02 апр 2024 16:05:00 Источник Nasdaq GlobeNewswire
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference

26 мар 2024 16:05:00 Источник Nasdaq GlobeNewswire

<<
<
1
>

Принимаю NetDania's website uses cookies. By continuing browsing our website, you agree to our Правила в отношении Cookies, Политика конфиденциальности and Правила и условия.